RESUMO
Objectives: To investigate the risk factors of patients with Klebsiella pneumoniae (KP) bloodstream infection (BSI) with a focus on antimicrobial resistance and virulence factors. Methods: All KP BSI patients (n = 579) from six general hospitals during a 1 year period were included in this study. The risk factors of hosts and causative KP isolates were assessed to determine associations with the 30 day mortality of KP BSI patients by multivariate Cox hazards modelling. Results: The 30 day mortality rate of KP BSI patients was 16.9% (98/579). Among the host-associated factors, increased SOFA score and leucopenia status exhibited strong associations with increased 30 day mortality. Among the pathogenic factors, carriage of the pks gene cluster (adjusted HR 1.80; 95% CI 1.16-2.79) was a risk factor, especially when accompanied by MDR. In this regard, KP isolates of the wzi50 capsular type (n = 22) frequently harboured pks (63.6%, 14/22) and ybtA (68.2%, n = 15) and mostly exhibited MDR (63.6%, n = 14), resulting in increased 30 day mortality. In contrast, hypermucoviscous KP isolates showed an inverse association with 30 day mortality (adjusted HR 0.55; 95% CI 0.33-0.90). Conclusions: Despite the reported virulence of hypermucoviscous KP strains, they were associated with good prognoses in KP BSI patients. Importantly, carriage of the pks gene cluster, which is responsible for the synthesis of colibactin, was a relevant marker of early mortality.
Assuntos
Farmacorresistência Bacteriana , Infecções por Klebsiella/mortalidade , Klebsiella pneumoniae/efeitos dos fármacos , Klebsiella pneumoniae/patogenicidade , Sepse/microbiologia , Fatores de Virulência/análise , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/isolamento & purificação , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Risco , Sepse/mortalidade , Análise de SobrevidaRESUMO
BACKGROUND: The emergence of carbapenem resistance among gram-negative bacilli (GNB), mediated by carbapenemase production, has necessitated the development of a simple and accurate device for detecting minimum inhibitory concentrations (MICs) and resistance mechanisms, especially carbapenemase production. We evaluated the performance of the BD Phoenix NMIC-500 panel (BD Diagnostic Systems, Sparks, MD, USA) for antimicrobial susceptibility testing (AST) and carbapenemase-producing organism (CPO) detection. METHODS: We used 450 non-duplicate clinical GNB isolates from six general hospitals in Korea (409 Enterobacteriaceae and 41 glucose non-fermenting bacilli [GNFB] isolates). AST for meropenem, imipenem, ertapenem, ceftazidime, and ceftazidime/avibactam, and CPO detection were performed using the Phoenix NMIC-500 panel. Broth microdilution was used as the reference method for AST. The rates of categorical agreement (CA), essential agreement (EA), minor error (mE), major error (ME), and very major error (VME) were calculated in each antimicrobial. In addition, PCR and sequencing were performed to evaluate the accuracy of CPO detection by the BD Phoenix NMIC-500 panel, and the rate of correct identification was calculated. RESULTS: The CA rates were >90% for all antimicrobials tested with the Enterobacteriaceae isolates, except for imipenem (87.2%). The GNFB CA rates ranged from 92.7% to 100% for all antimicrobials. The ME rates were 1.7% for Enterobacteriaceae and 0% for GNFB. The panel identified 97.2% (243/250) of the carbapenemase-producing isolates. CONCLUSIONS: The BD Phoenix NMIC-500 panel shows promise for AST and CPO detection.
Assuntos
Bactérias Gram-Negativas/isolamento & purificação , Testes de Sensibilidade Microbiana/métodos , Antibacterianos/farmacologia , Bacillus/efeitos dos fármacos , Bacillus/isolamento & purificação , Proteínas de Bactérias/genética , Farmacorresistência Bacteriana/efeitos dos fármacos , Farmacorresistência Bacteriana/genética , Enterobacteriaceae/efeitos dos fármacos , Enterobacteriaceae/isolamento & purificação , beta-Lactamases/genéticaRESUMO
The objectives of this study were to evaluate the performance of the BD Phoenix™ M50 system with two antimicrobial susceptibility testing (AST) panels against clinical isolates in South Korea and the accuracy of determining carbapenem and colistin susceptibility compared with reference methods. A total of 825 nonduplicated clinical isolates were included in this study. Bacterial identification was performed using Bruker Biotyper and 16S rDNA sequencing. Antimicrobial susceptibilities were tested by disk diffusion, broth microdilution, and agar dilution methods. AST with the Phoenix system was performed following the manufacturer's instructions. The categorical agreement (CA), very major error (VME), major error (ME), and minor error (mE) rates were calculated for each antibiotic. CA rates between the results of the Phoenix system and reference methods were more than 90% for most antibiotics except for ciprofloxacin in enterococci (82.7%, 163/197) and cefepime in Acinetobacter species (88.9%, 88/99). VME and ME rates were less than 3% for all the antibiotics tested in this study. Minimum inhibitory concentration (MIC) values for carbapenem and colistin determined by the Phoenix system were highly correlated with those of dilution methods, exhibiting 99.2% (384/387), 96.7% (374/387), and 98.5% (129/131) of the agreement rate within onefold dilution difference for imipenem, meropenem, and colistin, respectively. The BD Phoenix M50™ system showed reliable performance for AST in clinical microbiology laboratories and for detecting carbapenem and colistin resistance in Gram-negative clinical isolates.